Adenovirus vectors for gene therapy

Einfeld DA, Roelvink PW. 2002. Advances towards targetable adenovirus targetable adenovirus vectors for gene therapy. Curr Opin Mol Ther. 4 444-451. 

Nadeau I, Kamen A (2003). Production of adenovirus vector for gene therapy. Bio-technol. Adv. 20 475-489. 

Roitsch C, Achstetter T, Benchaibi M, et al. (2001). Characterization and quality control of recombinant adenovirus vectors for gene therapy. J. Chromatog. B. 752 263-280. 

D.M.F. Prazeres, Institute for Biotechnology and Bioengineering, Center for Biological and Chemical Engineering, Institute Superior Tecnico, Lisbon, Portugal, Production and Purification of Adenovirus Vectors for Gene Therapy... 

Production and Purification of Adenovirus Vectors for Gene Therapy... 

Glasgow JN, Everts M, Curiel DT (2006) Transductional targeting of adenovirus vectors for gene therapy Cancer Gene Ther 13 830-844... 

As potential vectors for gene therapy, adenoviruses display a number of both advantages and disadvantages (Table 14.3), and they have been used in over 300 gene therapy trials to date. Their major advantage relates to their ability to infect non-dividing cells efficiently and the usually... 

Table 14.3 Some characteristic advantages and disadvantages of adenoviruses as potential vectors for gene therapy. Refer to text for further details...

McConnell MJ, Imperiale MJ. 2004. Biology of adenovirus and its use as a vector for gene therapy. Hum Gene Ther. 15 1022-1033. 

Despite these apparent drawbacks, the adenovirus remains a popular vector for gene therapy due to its high gene transfer efficiency and high level of expression in a wide variety of cell types. Some effort has been made to modify the inflammatory and immunogenic properties of the adenovirus capsid, but so far little progress has been made. 

Amalfitano A, Parks RJ. 2002. Separating fact from fiction Assessing the potential of modified adenovirus vectors for use in human gene therapy. Curr Gene Ther. 2 111-133. 

W. R. Martiniello, A. J. Garcia, M. M. Daja, P. Russell, G. W. Both, P. L. Molloy, L. J. Lockett, and P. J. Russell, In vivo gene therapy for prostate cancer preclinical evaluation of two different enzyme-directed prodrug therapy systems delivered by identical adenovirus vectors, Hum. Gene Ther. 9 1617 (1998). 

Sun, B. et al. (2003). Packaging of an AAV vector encoding human acid alpha-glucosidase for gene therapy in glycogen storage disease type II with a modified hybrid adenovirus-AAV vector. Mol. Ther. 7, 467-477. 

---